Journal ArticleDOI
Cancer-related inflammation.
TLDR
The role of cancer-associated inflammation and the particular role of MIF in malignant disease is discussed and there is evidence that the cytokine is produced by both malignant cells and infiltrating leukocytes.Citations
More filters
Journal ArticleDOI
Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?
TL;DR: Current knowledge is reviewed on the ability of both normal and tumor thyroid cells to secrete CXCL8, the most studied one in human malignancies, displaying multifaceted pro-tumorigenic effects, which include proangiogenetic, cytoproliferative, and pro-metastatic effects.
Journal ArticleDOI
Cannabinoids in the Pathophysiology of Skin Inflammation.
Cristian Scheau,Ioana Anca Badarau,Livia-Gratiela Mihai,Andreea-Elena Scheau,Daniel Octavian Costache,Carolina Constantin,Daniela Calina,Constantin Caruntu,Raluca Simona Costache,Ana Caruntu +9 more
TL;DR: In vivo and in vitro studies that employed either phyto-, endo-, or synthetic cannabinoids were considered and the potential role of cannabinoids as antitumoral drugs is explored in relation to the inflammatory component of skin cancer.
Journal ArticleDOI
Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients
TL;DR: SIRI may be a convenient, low cost and reliable tumor marker for predicting prognosis in HCC patients and was more predictive of overall survival that the AFP level or Child-Pugh score.
Journal ArticleDOI
Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Rong Liang Shi,Ning Qu,Ting Xian Luo,Jun Xiang,Tian Liao,Guo Hua Sun,Yu Wang,Yu-Long Wang,Cai Ping Huang,Qinghai Ji +9 more
TL;DR: Positive PD-L1 expression in tumor tissue is important in determining aggressiveness of PTC and could predict the prognosis of patients, and inhibition of PD- l1 is suggested as a potential strategy for the treatment of advanced PTC with high expression.
Journal ArticleDOI
Cancer immunotherapy: how low-level ionizing radiation can play a key role
TL;DR: It is postulate that, based on epidemiological and experimental data amassed over the last few decades, whole- or half-body irradiations with LLR should be systematically examined for its potential to be a viable immunotherapeutic treatment option for patients with systemic cancer.
References
More filters
Journal ArticleDOI
Cancer-related inflammation.
TL;DR: The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment.
Journal ArticleDOI
Inflammation and cancer: back to Virchow?
TL;DR: A rationale for the use of cytokine and chemokine blockade, and further investigation of non-steroidal anti-inflammatory drugs, in the chemoprevention and treatment of malignant diseases is provided.
Journal ArticleDOI
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.
Florian R. Greten,Lars Eckmann,Tim F. Greten,Jin Mo Park,Zhi-Wei Li,Laurence J. Egan,Laurence J. Egan,Martin F. Kagnoff,Michael Karin +8 more
TL;DR: It is shown that although deletion of IKKbeta in intestinal epithelial cells does not decrease inflammation, it leads to a dramatic decrease in tumor incidence without affecting tumor size, which is linked to increased epithelial apoptosis during tumor promotion.
Journal ArticleDOI
NF-κB functions as a tumour promoter in inflammation-associated cancer
Eli Pikarsky,Rinnat M. Porat,Ilan Stein,Rinat Abramovitch,Sharon Amit,Shafika Kasem,Elena Gutkovich-Pyest,Simcha Urieli-Shoval,Eithan Galun,Yinon Ben-Neriah +9 more
TL;DR: It is shown that the inflammatory process triggers hepatocyte NF-κB through upregulation of tumour-necrosis factor-α (TNFα) in adjacent endothelial and inflammatory cells, and is therefore a potential target for cancer prevention in chronic inflammatory diseases.
Journal ArticleDOI
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
TL;DR: A number of clinical trials of TNF-α antagonists alone, and in combination with other therapies, are currently underway in cancer patients, and there are suggestions of activity against advanced disease in advanced ovarian and renal cell cancer.